Korean J Physiol Pharmacol.  2014 Aug;18(4):279-288. 10.4196/kjpp.2014.18.4.279.

A Review on Chemical-Induced Inflammatory Bowel Disease Models in Rodents

• Randhawa P
• Singh K
• Singh N
• Jaggi AS

• KMID: 2285521
• DOI: http://doi.org/10.4196/kjpp.2014.18.4.279

Abstract

Ulcerative colitis and Crohn's disease are a set of chronic, idiopathic, immunological and relapsing inflammatory disorders of the gastrointestinal tract referred to as inflammatory bowel disorder (IBD). Although the etiological factors involved in the perpetuation of IBD remain uncertain, development of various animal models provides new insights to unveil the onset and the progression of IBD. Various chemical-induced colitis models are widely used on laboratory scale. Furthermore, these models closely mimic morphological, histopathological and symptomatical features of human IBD. Among the chemical-induced colitis models, trinitrobenzene sulfonic acid (TNBS)-induced colitis, oxazolone induced-colitis and dextran sulphate sodium (DSS)-induced colitis models are most widely used. TNBS elicits Th-1 driven immune response, whereas oxazolone predominantly exhibits immune response of Th-2 phenotype. DSS-induced colitis model also induces changes in Th-1/Th-2 cytokine profile. The present review discusses the methodology and rationale of using various chemical-induced colitis models for evaluating the pathogenesis of IBD.

Keyword

Acetic acid; DSS; Inflammatory bowel disease; Oxazolone; TNBS

MeSH Terms

Acetic Acid
Colitis
Colitis, Ulcerative
Crohn Disease
Dextrans
Gastrointestinal Tract
Humans
Inflammatory Bowel Diseases*
Models, Animal
Oxazolone
Phenotype
Rodentia*
Sodium
Acetic Acid
Dextrans
Oxazolone
Sodium

Reference

1. Molodecky NA, Soon IS, Rabi DM, Ghali WA, Ferris M, Chernoff G, Benchimol EI, Panaccione R, Ghosh S, Barkema HW, Kaplan GG. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2012; 142:46–54. PMID: 22001864.

2. Büsch K, Ludvigsson JF, Ekström-Smedby K, Ekbom A, Askling J, Neovius M. Nationwide prevalence of inflammatory bowel disease in Sweden: a population-based register study. Aliment Pharmacol Ther. 2014; 39:57–68. PMID: 24127738.

3. Koch TR, Yuan LX, Stryker SJ, Ratliff P, Telford GL, Opara EC. Total antioxidant capacity of colon in patients with chronic ulcerative colitis. Dig Dis Sci. 2000; 45:1814–1819. PMID: 11052325.

4. Cetinkaya A, Bulbuloglu E, Kantarceken B, Ciralik H, Kurutas EB, Buyukbese MA, Gumusalan Y. Effects of L-carnitine on oxidant/antioxidant status in acetic acid-induced colitis. Dig Dis Sci. 2006; 51:488–494. PMID: 16614957.

5. Danese S, Angelucci E. New and emerging biologics in the treatment of inflammatory bowel disease: quo vadis? Gastroenterol Clin Biol. 2009; 33(Suppl 3):S217–S227. PMID: 20117345.

6. Carter MJ, Lobo AJ, Travis SP. IBD Section, British Society of Gastroenterology. Guidelines for the management of inflammatory bowel disease in adults. Gut. 2004; 53(Suppl 5):V1–V16. PMID: 15306569.

7. Fuss IJ, Neurath M, Boirivant M, Klein JS, de la Motte C, Strong SA, Fiocchi C, Strober W. Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn's disease LP cells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-5. J Immunol. 1996; 157:1261–1270. PMID: 8757634.

8. Parronchi P, Romagnani P, Annunziato F, Sampognaro S, Becchio A, Giannarini L, Maggi E, Pupilli C, Tonelli F, Romagnani S. Type 1 T-helper cell predominance and interleukin-12 expression in the gut of patients with Crohn's disease. Am J Pathol. 1997; 150:823–832. PMID: 9060820.

9. Katz LH, Kopylov U, Fudim E, Yavzori M, Picard O, Ungar B, Eliakim R, Ben-Horin S, Chowers Y. Expression of IL-2, IL-17 and TNF-alpha in patients with Crohn's disease treated with anti-TNF antibodies. Clin Res Hepatol Gastroenterol. 2014; [Epub ahead of print].

10. Papaconstantinou I, Zeglinas C, Gazouli M, Nastos K, Yiallourou A, Papalois A, Tzathas C. The impact of perioperative anti-TNF treatment on anastomosis-related complications in Crohn's disease patients. A critical review. J Gastrointest Surg. 2014; 18:1216–1224. PMID: 24599780.

11. Camoglio L, Te Velde AA, Tigges AJ, Das PK, Van Deventer SJ. Altered expression of interferon-gamma and interleukin-4 in inflammatory bowel disease. Inflamm Bowel Dis. 1998; 4:285–290. PMID: 9836081.

12. Melgar S, Yeung MM, Bas A, Forsberg G, Suhr O, Oberg A, Hammarstrom S, Danielsson A, Hammarstrom ML. Overexpression of interleukin 10 in mucosal T cells of patients with active ulcerative colitis. Clin Exp Immunol. 2003; 134:127–137. PMID: 12974765.

13. Fuss IJ, Heller F, Boirivant M, Leon F, Yoshida M, Fichtner-Feigl S, Yang Z, Exley M, Kitani A, Blumberg RS, Mannon P, Strober W. Nonclassical CD1d-restricted NK T cells that produce IL-13 characterize an atypical Th2 response in ulcerative colitis. J Clin Invest. 2004; 113:1490–1497. PMID: 15146247.

14. Rana SV, Sharma S, Kaur J, Prasad KK, Sinha SK, Kochhar R, Malik A, Morya RK. Relationship of cytokines, oxidative stress and GI motility with bacterial overgrowth in ulcerative colitis patients. J Crohns Colitis. 2014; [Epub ahead of print].

15. Ellrichmann M, Wietzke-Braun P, Dhar S, Nikolaus S, Arlt A, Bethge J, Kuehbacher T, Wintermeyer L, Balschun K, Klapper W, Schreiber S, Fritscher-Ravens A. Endoscopic ultrasound of the colon for the differentiation of Crohn's disease and ulcerative colitis in comparison with healthy controls. Aliment Pharmacol Ther. 2014; 39:823–833. PMID: 24612000.

16. Morris GP, Beck PL, Herridge MS, Depew WT, Szewczuk MR, Wallace JL. Hapten-induced model of chronic inflammation and ulceration in the rat colon. Gastroenterology. 1989; 96:795–803. PMID: 2914642.

17. da Silva MS, Sánchez-Fidalgo S, Talero E, Cárdeno A, da Silva MA, Villegas W, Souza Brito AR, de La Lastra CA. Antiinflammatory intestinal activity of Abarema cochliacarpos (Gomes) Barneby & Grimes in TNBS colitis model. J Ethnopharmacol. 2010; 128:467–475. PMID: 20083187.

18. de Almeida AB, Sánchez-Hidalgo M, Martín AR, Luiz-Ferreira A, Trigo JR, Vilegas W, dos Santos LC, Souza-Brito AR, de la Lastra CA. Anti-inflammatory intestinal activity of Arctium lappa L. (Asteraceae) in TNBS colitis model. J Ethnopharmacol. 2013; 146:300–310. PMID: 23313393.

19. Moncada DM, Kammanadiminti SJ, Chadee K. Mucin and Toll-like receptors in host defense against intestinal parasites. Trends Parasitol. 2003; 19:305–311. PMID: 12855381.

20. Dharmani P, Leung P, Chadee K. Tumor necrosis factor-α and Muc2 mucin play major roles in disease onset and progression in dextran sodium sulphate-induced colitis. PLoS One. 2011; 6:e25058. PMID: 21949848.

21. Cheah KY, Bastian SE, Acott TM, Abimosleh SM, Lymn KA, Howarth GS. Grape seed extract reduces the severity of selected disease markers in the proximal colon of dextran sulphate sodium-induced colitis in rats. Dig Dis Sci. 2013; 58:970–977. PMID: 23143736.

22. Zhang HQ, Ding TT, Zhao JS, Yang X, Zhang HX, Zhang JJ, Cui YL. Therapeutic effects of Clostridium butyricum on experimental colitis induced by oxazolone in rats. World J Gastroenterol. 2009; 15:1821–1828. PMID: 19370778.

23. Yang J, Zhao J, Nakaguchi T, Gregersen H. Biomechanical changes in oxazolone-induced colitis in BALB/C mice. J Biomech. 2009; 42:811–817. PMID: 19264309.

24. Lee J, Yamamoto T, Kuramoto H, Kadowaki M. TRPV1 expressing extrinsic primary sensory neurons play a protective role in mouse oxazolone-induced colitis. Auton Neurosci. 2012; 166:72–76. PMID: 21855422.

25. Millar AD, Rampton DS, Chander CL, Claxson AW, Blades S, Coumbe A, Panetta J, Morris CJ, Blake DR. Evaluating the antioxidant potential of new treatments for inflammatory bowel disease using a rat model of colitis. Gut. 1996; 39:407–415. PMID: 8949646.

26. Hagar HH, El-Medany A, El-Eter E, Arafa M. Ameliorative effect of pyrrolidinedithiocarbamate on acetic acid-induced colitis in rats. Eur J Pharmacol. 2007; 554:69–77. PMID: 17112501.

27. Mousavizadeh K, Rahimian R, Fakhfouri G, Aslani FS, Ghafourifar P. Anti-inflammatory effects of 5-HT receptor antagonist, tropisetron on experimental colitis in rats. Eur J Clin Invest. 2009; 39:375–383. PMID: 19302562.

28. Al-Rejaie SS, Abuohashish HM, Al-Enazi MM, Al-Assaf AH, Parmar MY, Ahmed MM. Protective effect of naringenin on acetic acid-induced ulcerative colitis in rats. World J Gastroenterol. 2013; 19:5633–5644. PMID: 24039355.

29. Narushima S, Spitz DR, Oberley LW, Toyokuni S, Miyata T, Gunnett CA, Buettner GR, Zhang J, Ismail H, Lynch RG, Berg DJ. Evidence for oxidative stress in NSAID-induced colitis in IL10-/- mice. Free Radic Biol Med. 2003; 34:1153–1166. PMID: 12706496.

30. Pawar AT, Anap RM, Ghodasara JV, Kuchekar BS. Protective Effect of Hydroalcoholic Root Extract of Rubia cordifolia in Indomethacin-Induced Enterocolitis in Rats. Indian J Pharm Sci. 2011; 73:250–253. PMID: 22303076.

31. Moyana TN, Lalonde JM. Carrageenan-induced intestinal injury in the rat--a model for inflammatory bowel disease. Ann Clin Lab Sci. 1990; 20:420–426. PMID: 2073092.

32. Pricolo VE, Madhere SM, Finkelstein SD, Reichner JS. Effects of lambda-carrageenan induced experimental enterocolitis on splenocyte function and nitric oxide production. J Surg Res. 1996; 66:6–11. PMID: 8954824.

33. Fitzpatrick LR, Wang J, Le T. Gliotoxin, an inhibitor of nuclear factor-kappa B, attenuates peptidoglycan-polysaccharide-induced colitis in rats. Inflamm Bowel Dis. 2002; 8:159–167. PMID: 11979135.

34. Reingold L, Rahal K, Schmiedlin-Ren P, Rittershaus AC, Bender D, Owens SR, Adler J, Zimmermann EM. Development of a peptidoglycan-polysaccharide murine model of Crohn's disease: effect of genetic background. Inflamm Bowel Dis. 2013; 19:1238–1244. PMID: 23619717.

35. Cheon GJ, Cui Y, Yeon DS, Kwon SC, Park BG. Mechanisms of motility change on trinitrobenzenesulfonic Acid-induced colonic inflammation in mice. Korean J Physiol Pharmacol. 2012; 16:437–446. PMID: 23269907.

36. Isik F, Tunali Akbay T, Yarat A, Genc Z, Pisiriciler R, Caliskan-Ak E, Cetinel S, Altıntas A, Sener G. Protective effects of black cumin (Nigella sativa) oil on TNBS-induced experimental colitis in rats. Dig Dis Sci. 2011; 56:721–730. PMID: 20658190.

37. Elson CO, Sartor RB, Tennyson GS, Riddell RH. Experimental models of inflammatory bowel disease. Gastroenterology. 1995; 109:1344–1367. PMID: 7557106.

38. Yu Q, Zhu S, Zhou R, Yi F, Bing Y, Huang S, Wang Z, Wang C, Xia B. Effects of sinomenine on the expression of microRNA-155 in 2,4,6-trinitrobenzenesulfonic acid-induced colitis in mice. PLoS One. 2013; 8:e73757. PMID: 24066068.

39. Neurath MF, Fuss I, Kelsall BL, Stüber E, Strober W. Antibodies to interleukin 12 abrogate established experimental colitis in mice. J Exp Med. 1995; 182:1281–1290. PMID: 7595199.

40. Boirivant M, Fuss IJ, Chu A, Strober W. Oxazolone colitis: A murine model of T helper cell type 2 colitis treatable with antibodies to interleukin 4. J Exp Med. 1998; 188:1929–1939. PMID: 9815270.

41. Dohi T, Fujihashi K, Kiyono H, Elson CO, McGhee JR. Mice deficient in Th1- and Th2-type cytokines develop distinct forms of hapten-induced colitis. Gastroenterology. 2000; 119:724–733. PMID: 10982767.

42. Qin HY, Wu JC, Tong XD, Sung JJ, Xu HX, Bian ZX. Systematic review of animal models of post-infectious/post-inflammatory irritable bowel syndrome. J Gastroenterol. 2011; 46:164–174. PMID: 20848144.

43. Ikeda M, Takeshima F, Isomoto H, Shikuwa S, Mizuta Y, Ozono Y, Kohno S. Simvastatin attenuates trinitrobenzene sulfonic acid-induced colitis, but not oxazalone-induced colitis. Dig Dis Sci. 2008; 53:1869–1875. PMID: 18049901.

44. Takagi T, Naito Y, Mizushima K, Akagiri S, Suzuki T, Hirata I, Omatsu T, Handa O, Kokura S, Ichikawa H, Yoshikawa T. Inhalation of carbon monoxide ameliorates TNBS-induced colitis in mice through the inhibition of TNF-α expression. Dig Dis Sci. 2010; 55:2797–2804. PMID: 20094779.

45. Martínez-Moya P, Romero-Calvo I, Requena P, Hernández-Chirlaque C, Aranda CJ, González R, Zarzuelo A, Suárez MD, Martínez-Augustin O, Marín JJ, de Medina FS. Dose-dependent antiinflammatory effect of ursodeoxycholic acid in experimental colitis. Int Immunopharmacol. 2013; 15:372–380. PMID: 23246254.

46. Park SY, Ku SK, Lee ES, Kim JA. 1,3-Diphenylpropenone ameliorates TNBS-induced rat colitis through suppression of NF-κB activation and IL-8 induction. Chem Biol Interact. 2012; 196:39–49. PMID: 22410118.

47. Liu DY, Guan YM, Zhao HM, Yan DM, Tong WT, Wan PT, Zhu WF, Liu HN, Liang XL. The protective and healing effects of Si Shen Wan in trinitrobenzene sulphonic acid-induced colitis. J Ethnopharmacol. 2012; 143:435–440. PMID: 22751005.

48. Yang XL, Guo TK, Wang YH, Gao MT, Qin H, Wu YJ. Therapeutic effect of ginsenoside Rd in rats with TNBS-induced recurrent ulcerative colitis. Arch Pharm Res. 2012; 35:1231–1239. PMID: 22864746.

49. Jurjus AR, Khoury NN, Reimund JM. Animal models of inflammatory bowel disease. J Pharmacol Toxicol Methods. 2004; 50:81–92. PMID: 15385082.

50. Gaudio E, Taddei G, Vetuschi A, Sferra R, Frieri G, Ricciardi G, Caprilli R. Dextran sulfate sodium (DSS) colitis in rats: clinical, structural, and ultrastructural aspects. Dig Dis Sci. 1999; 44:1458–1475. PMID: 10489934.

51. Okayasu I, Hatakeyama S, Yamada M, Ohkusa T, Inagaki Y, Nakaya R. A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. Gastroenterology. 1990; 98:694–702. PMID: 1688816.

52. Tran CD, Ball JM, Sundar S, Coyle P, Howarth GS. The role of zinc and metallothionein in the dextran sulfate sodium-induced colitis mouse model. Dig Dis Sci. 2007; 52:2113–2121. PMID: 17410436.

53. Perše M, Cerar A. Dextran sodium sulphate colitis mouse model: traps and tricks. J Biomed Biotechnol. 2012; 2012:718617. PMID: 22665990.

54. Geier MS, Smith CL, Butler RN, Howarth GS. Small-intestinal manifestations of dextran sulfate sodium consumption in rats and assessment of the effects of Lactobacillus fermentum BR11. Dig Dis Sci. 2009; 54:1222–1228. PMID: 19005763.

55. Ohtsuka Y, Sanderson IR. Dextran sulfate sodium-induced inflammation is enhanced by intestinal epithelial cell chemokine expression in mice. Pediatr Res. 2003; 53:143–147. PMID: 12508094.

56. Ni J, Chen SF, Hollander D. Effects of dextran sulphate sodium on intestinal epithelial cells and intestinal lymphocytes. Gut. 1996; 39:234–241. PMID: 8991862.

57. Dai C, Zheng CQ, Meng FJ, Zhou Z, Sang LX, Jiang M. VSL#3 probiotics exerts the anti-inflammatory activity via PI3k/Akt and NF-κB pathway in rat model of DSS-induced colitis. Mol Cell Biochem. 2013; 374:1–11. PMID: 23271629.

58. Andújar I, Ríos JL, Giner RM, Miguel Cerdá J, Recio Mdel C. Beneficial effect of shikonin on experimental colitis induced by dextran sulfate sodium in BALB/c mice. Evid Based Complement Alternat Med. 2012; 2012:271606. PMID: 23346196.

59. Dieleman LA, Palmen MJ, Akol H, Bloemena E, Peña AS, Meuwissen SG, Van Rees EP. Chronic experimental colitis induced by dextran sulphate sodium (DSS) is characterized by Th1 and Th2 cytokines. Clin Exp Immunol. 1998; 114:385–391. PMID: 9844047.

60. Melgar S, Karlsson A, Michaëlsson E. Acute colitis induced by dextran sulfate sodium progresses to chronicity in C57BL/6 but not in BALB/c mice: correlation between symptoms and inflammation. Am J Physiol Gastrointest Liver Physiol. 2005; 288:G1328–G1338. PMID: 15637179.

61. Perše M, Cerar A. Dextran sodium sulphate colitis mouse model: traps and tricks. J Biomed Biotechnol. 2012; 2012:718617. PMID: 22665990.

62. Morgan ME, Zheng B, Koelink PJ, van de Kant HJ, Haazen LC, van Roest M, Garssen J, Folkerts G, Kraneveld AD. New perspective on dextran sodium sulfate colitis: antigen-specific T cell development during intestinal inflammation. PLoS One. 2013; 8:e69936. PMID: 23936123.

63. Dong F, Zhang L, Hao F, Tang H, Wang Y. Systemic responses of mice to dextran sulfate sodium-induced acute ulcerative colitis using 1H NMR spectroscopy. J Proteome Res. 2013; 12:2958–2966. PMID: 23651354.

64. Michel V, Yuan Z, Ramsubir S, Bakovic M. Choline transport for phospholipid synthesis. Exp Biol Med (Maywood). 2006; 231:490–504. PMID: 16636297.

65. Poritz LS, Garver KI, Green C, Fitzpatrick L, Ruggiero F, Koltun WA. Loss of the tight junction protein ZO-1 in dextran sulfate sodium induced colitis. J Surg Res. 2007; 140:12–19. PMID: 17418867.

66. Singh K, Jaggi AS, Singh N. Exploring the ameliorative potential of Punica granatum in dextran sulfate sodium induced ulcerative colitis in mice. Phytother Res. 2009; 23:1565–1574. PMID: 19367659.

67. Dieleman LA, Peña AS, Meuwissen SG, van Rees EP. Role of animal models for the pathogenesis and treatment of inflammatory bowel disease. Scand J Gastroenterol Suppl. 1997; 223:99–104. PMID: 9200314.

68. Rijcken EM, Laukoetter MG, Anthoni C, Meier S, Mennigen R, Spiegel HU, Bruewer M, Senninger N, Vestweber D, Krieglstein CF. Immunoblockade of PSGL-1 attenuates established experimental murine colitis by reduction of leukocyte rolling. Am J Physiol Gastrointest Liver Physiol. 2004; 287:G115–G124. PMID: 15001428.

69. Iwaya H, Fujii N, Hagio M, Hara H, Ishizuka S. Contribution of dipeptidyl peptidase IV to the severity of dextran sulfate sodium-induced colitis in the early phase. Biosci Biotechnol Biochem. 2013; 77:1461–1466. PMID: 23832365.

70. Kumar G K, Dhamotharan R, Kulkarni NM, Honnegowda S, Murugesan S. Embelin ameliorates dextran sodium sulfate-induced colitis in mice. Int Immunopharmacol. 2011; 11:724–731. PMID: 21296695.

71. Coburn LA, Gong X, Singh K, Asim M, Scull BP, Allaman MM, Williams CS, Rosen MJ, Washington MK, Barry DP, Piazuelo MB, Casero RA Jr, Chaturvedi R, Zhao Z, Wilson KT. L-arginine supplementation improves responses to injury and inflammation in dextran sulfate sodium colitis. PLoS One. 2012; 7:e33546. PMID: 22428068.

72. Laroui H, Ingersoll SA, Liu HC, Baker MT, Ayyadurai S, Charania MA, Laroui F, Yan Y, Sitaraman SV, Merlin D. Dextran sodium sulfate (DSS) induces colitis in mice by forming nano-lipocomplexes with medium-chain-length fatty acids in the colon. PLoS One. 2012; 7:e32084. PMID: 22427817.

73. Jadhav SR, Shandilya UK, Kansal VK. Exploring the ameliorative potential of probiotic Dahi containing Lactobacillus acidophilus and Bifidobacterium bifidum on dextran sodium sulphate induced colitis in mice. J Dairy Res. 2013; 80:21–27. PMID: 23317563.

74. Kleiveland CR, Hult LT, Spetalen S, Kaldhusdal M, Christofferesen TE, Bengtsson O, Romarheim OH, Jacobsen M, Lea T. The noncommensal bacterium Methylococcus capsulatus (Bath) ameliorates dextran sulfate (Sodium Salt)-Induced Ulcerative Colitis by influencing mechanisms essential for maintenance of the colonic barrier function. Appl Environ Microbiol. 2013; 79:48–56. PMID: 23064342.

75. Köhnke T, Gomolka B, Bilal S, Zhou X, Sun Y, Rothe M, Baumgart DC, Weylandt KH. Acetylsalicylic Acid reduces the severity of dextran sodium sulfate-induced colitis and increases the formation of anti-inflammatory lipid mediators. Biomed Res Int. 2013; 2013:748160. PMID: 24083240.

76. Liu L, Liu YL, Liu GX, Chen X, Yang K, Yang YX, Xie Q, Gan HK, Huang XL, Gan HT. Curcumin ameliorates dextran sulfate sodium-induced experimental colitis by blocking STAT3 signaling pathway. Int Immunopharmacol. 2013; 17:314–320. PMID: 23856612.

77. Kato E, Yamane S, Nomura R, Matsumoto K, Tashima K, Horie S, Saito T, Fujino H, Murayama T. Dysfunction of neurogenic VIP-mediated relaxation in mouse distal colon with dextran sulfate sodium-induced colitis. Pharmacol Res. 2012; 65:204–212. PMID: 21939768.

78. Cooper HS, Murthy SN, Shah RS, Sedergran DJ. Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Lab Invest. 1993; 69:238–249. PMID: 8350599.

79. Giner E, Recio MC, Ríos JL, Giner RM. Oleuropein protects against dextran sodium sulfate-induced chronic colitis in mice. J Nat Prod. 2013; 76:1113–1120. PMID: 23758110.

80. Trivedi PP, Jena GB. Dextran sulfate sodium-induced ulcerative colitis leads to increased hematopoiesis and induces both local as well as systemic genotoxicity in mice. Mutat Res. 2012; 744:172–183. PMID: 22414559.

81. Kojima R, Kuroda S, Ohkishi T, Nakamaru K, Hatakeyama S. Oxazolone-induced colitis in BALB/C mice: a new method to evaluate the efficacy of therapeutic agents for ulcerative colitis. J Pharmacol Sci. 2004; 96:307–313. PMID: 15539761.

82. Engel MA, Khalil M, Siklosi N, Mueller-Tribbensee SM, Neuhuber WL, Neurath MF, Becker C, Reeh PW. Opposite effects of substance P and calcitonin gene-related peptide in oxazolone colitis. Dig Liver Dis. 2012; 44:24–29. PMID: 22018693.

83. Charles PC, Weber KS, Cipriani B, Brosnan CF. Cytokine, chemokine and chemokine receptor mRNA expression in different strains of normal mice: implications for establishment of a Th1/Th2 bias. J Neuroimmunol. 1999; 100:64–73. PMID: 10695717.

84. Zhang HQ, Ding TT, Zhao JS, Yang X, Zhang HX, Zhang JJ, Cui YL. Therapeutic effects of Clostridium butyricum on experimental colitis induced by oxazolone in rats. World J Gastroenterol. 2009; 15:1821–1828. PMID: 19370778.

85. Abdin AA. Targeting sphingosine kinase 1 (SphK1) and apoptosis by colon-specific delivery formula of resveratrol in treatment of experimental ulcerative colitis in rats. Eur J Pharmacol. 2013; 718:145–153. PMID: 24055189.

86. Huang Z, Jiang Y, Yang Y, Shao J, Sun X, Chen J, Dong L, Zhang J. 3,3'-Diindolylmethane alleviates oxazolone-induced colitis through Th2/Th17 suppression and Treg induction. Mol Immunol. 2013; 53:335–344. PMID: 23085552.

87. Daniel C, Sartory NA, Zahn N, Schmidt R, Geisslinger G, Radeke HH, Stein JM. FTY720 ameliorates oxazolone colitis in mice by directly affecting T helper type 2 functions. Mol Immunol. 2007; 44:3305–3316. PMID: 17475330.

88. Ma Y, Semba S, Maemoto A, Takeuchi M, Kameshita I, Ishida A, Kato S, Katoh T, Liu Y, Taniguchi T. Oxazolone-induced over-expression of focal adhesion kinase in colonic epithelial cells of colitis mouse model. FEBS Lett. 2010; 584:3949–3954. PMID: 20682312.

89. MacPherson BR, Pfeiffer CJ. Experimental production of diffuse colitis in rats. Digestion. 1978; 17:135–150. PMID: 627326.

90. Noa M, Más R, Carbajal D, Valdés S. Effect of D-002 on acetic acid-induced colitis in rats at single and repeated doses. Pharmacol Res. 2000; 41:391–395. PMID: 10704261.

91. Sasaki S, Hirata I, Maemura K, Hamamoto N, Murano M, Toshina K, Katsu K. Prostaglandin E2 inhibits lesion formation in dextran sodium sulphate-induced colitis in rats and reduces the levels of mucosal inflammatory cytokines. Scand J Immunol. 2000; 51:23–28. PMID: 10632972.

92. González R, Rodríguez S, Romay C, Ancheta O, González A, Armesto J, Remirez D, Merino N. Anti-inflammatory activity of phycocyanin extract in acetic acid-induced colitis in rats. Pharmacol Res. 1999; 39:55–59. PMID: 10366332.

93. Gorgulu S, Yagci G, Kaymakcioglu N, Ozkara M, Kurt B, Ozcan A, Kaya O, Sadir S, Tufan T. Hyperbaric oxygen enhances the efficiency of 5-aminosalicylic acid in acetic acid-induced colitis in rats. Dig Dis Sci. 2006; 51:480–487. PMID: 16614956.

94. Nakhai LA, Mohammadirad A, Yasa N, Minaie B, Nikfar S, Ghazanfari G, Zamani MJ, Dehghan G, Jamshidi H, Boushehri VS, Khorasani R, Abdollahi M. Benefits of Zataria multiflora Boiss in experimental model of mouse inflammatory bowel disease. Evid Based Complement Alternat Med. 2007; 4:43–50. PMID: 17342240.

95. Bitiren M, Karakilcik AZ, Zerin M, Ozardali I, Selek S, Nazligul Y, Ozgonul A, Musa D, Uzunkoy A. Protective effects of selenium and vitamin E combination on experimental colitis in blood plasma and colon of rats. Biol Trace Elem Res. 2010; 136:87–95. PMID: 19774348.

96. Hartmann RM, Morgan Martins MI, Tieppo J, Fillmann HS, Marroni NP. Effect of Boswellia serrata on antioxidant status in an experimental model of colitis rats induced by acetic acid. Dig Dis Sci. 2012; 57:2038–2044. PMID: 22451119.

97. Daneshmand A, Rahimian R, Mohammadi H, Ejtemaee-Mehr S, Tavangar SM, Babaei Kelishomi R, Dehpour AR. Protective effects of lithium on acetic acid-induced colitis in rats. Dig Dis Sci. 2009; 54:1901–1907. PMID: 19082724.

98. Closa D, Folch-Puy E. Oxygen free radicals and the systemic inflammatory response. IUBMB Life. 2004; 56:185–191. PMID: 15230345.

99. Grisham MB, Granger DN. Neutrophil-mediated mucosal injury. Role of reactive oxygen metabolites. Dig Dis Sci. 1988; 33(3 Suppl):6S–15S. PMID: 2831016.

100. Kruidenier L, Verspaget HW. Review article: oxidative stress as a pathogenic factor in inflammatory bowel disease--radicals or ridiculous? Aliment Pharmacol Ther. 2002; 16:1997–2015. PMID: 12452933.

101. Wakefield AJ, Sawyerr AM, Dhillon AP, Pittilo RM, Rowles PM, Lewis AA, Pounder RE. Pathogenesis of Crohn's disease: multifocal gastrointestinal infarction. Lancet. 1989; 2:1057–1062. PMID: 2572794.

102. Dhillon AP, Anthony A, Sim R, Wakefield AJ, Sankey EA, Hudson M, Allison MC, Pounder RE. Mucosal capillary thrombi in rectal biopsies. Histopathology. 1992; 21:127–133. PMID: 1505929.

103. Joshi SV, Vyas BA, Shah PD, Shah DR, Shah SA, Gandhi TR. Protective effect of aqueous extract of Oroxylum indicum Linn. (root bark) against DNBS-induced colitis in rats. Indian J Pharmacol. 2011; 43:656–661. PMID: 22144769.

104. Keshavarzian A, Sedghi S, Kanofsky J, List T, Robinson C, Ibrahim C, Winship D. Excessive production of reactive oxygen metabolites by inflamed colon: analysis by chemiluminescence probe. Gastroenterology. 1992; 103:177–185. PMID: 1612325.

105. Dröge W. Free radicals in the physiological control of cell function. Physiol Rev. 2002; 82:47–95. PMID: 11773609.

106. Yalniz M, Demirel U, Orhan C, Bahcecioglu IH, Ozercan IH, Aygun C, Tuzcu M, Sahin K. Nadroparin sodium activates Nrf2/HO-1 pathway in acetic acid-induced colitis in rats. Inflammation. 2012; 35:1213–1221. PMID: 22350949.

107. Kannan N, Guruvayoorappan C. Protective effect of Bauhinia tomentosa on acetic acid induced ulcerative colitis by regulating antioxidant and inflammatory mediators. Int Immunopharmacol. 2013; 16:57–66. PMID: 23538025.

108. Iseri SO, Ersoy Y, Ercan F, Yuksel M, Atukeren P, Gumustas K, Alican I. The effect of sildenafil, a phosphodiesterase-5 inhibitor, on acetic acid-induced colonic inflammation in the rat. J Gastroenterol Hepatol. 2009; 24:1142–1148. PMID: 19638092.

109. Yamada Y, Marshall S, Specian RD, Grisham MB. A comparative analysis of two models of colitis in rats. Gastroenterology. 1992; 102:1524–1534. PMID: 1314749.

110. Tannahill CL, Stevenot SA, Campbell-Thompson M, Nick HS, Valentine JF. Induction and immunolocalization of manganese superoxide dismutase in acute acetic acid-induced colitis in the rat. Gastroenterology. 1995; 109:800–811. PMID: 7657108.

111. Mascolo N, Izzo AA, Autore G, Maiello FM, Di Carlo G, Capasso F. Acetic acid-induced colitis in normal and essential fatty acid deficient rats. J Pharmacol Exp Ther. 1995; 272:469–475. PMID: 7815363.

112. Hassan GS, Soliman GA. Design, synthesis and anti-ulcerogenic effect of some of furo-salicylic acid derivatives on acetic acid-induced ulcerative colitis. Eur J Med Chem. 2010; 45:4104–4112. PMID: 20573425.

113. Kolgazi M, Uslu U, Yuksel M, Velioglu-Ogunc A, Ercan F, Alican I. The role of cholinergic anti-inflammatory pathway in acetic acid-induced colonic inflammation in the rat. Chem Biol Interact. 2013; 205:72–80. PMID: 23810507.

114. Thippeswamy BS, Mahendran S, Biradar MI, Raj P, Srivastava K, Badami S, Veerapur VP. Protective effect of embelin against acetic acid induced ulcerative colitis in rats. Eur J Pharmacol. 2011; 654:100–105. PMID: 21185828.

115. Tahan G, Aytac E, Aytekin H, Gunduz F, Dogusoy G, Aydin S, Tahan V, Uzun H. Vitamin E has a dual effect of antiinflammatory and antioxidant activities in acetic acid-induced ulcerative colitis in rats. Can J Surg. 2011; 54:333–338. PMID: 21933527.

116. Xing J, Sun J, You H, Lv J, Sun J, Dong Y. Anti-inflammatory effect of 3,4-oxo-isopropylidene-shikimic acid on acetic acid-induced colitis in rats. Inflammation. 2012; 35:1872–1879. PMID: 22829139.

117. Rachmilewitz D, Karmeli F, Takabayashi K, Hayashi T, Leider-Trejo L, Lee J, Leoni LM, Raz E. Immunostimulatory DNA ameliorates experimental and spontaneous murine colitis. Gastroenterology. 2002; 122:1428–1441. PMID: 11984528.

118. Niu X, Fan T, Li W, Huang H, Zhang Y, Xing W. Protective effect of sanguinarine against acetic acid-induced ulcerative colitis in mice. Toxicol Appl Pharmacol. 2013; 267:256–265. PMID: 23352506.

119. Fitzpatrick LR, Wang J, Le T. Caffeic acid phenethyl ester, an inhibitor of nuclear factor-kappaB, attenuates bacterial peptidoglycan polysaccharide-induced colitis in rats. J Pharmacol Exp Ther. 2001; 299:915–920. PMID: 11714876.

120. Stadnicki A, Sartor RB, Janardham R, Majluf-Cruz A, Kettner CA, Adam AA, Colman RW. Specific inhibition of plasma kallikrein modulates chronic granulomatous intestinal and systemic inflammation in genetically susceptible rats. FASEB J. 1998; 12:325–333. PMID: 9506476.

121. Kaplan AP, Kay AB, Austen KF. A prealbumin activator of prekallikrein. 3. Appearance of chemotactic activity for human neutrophils by the conversion of human prekallikrein to kallikrein. J Exp Med. 1972; 135:81–97. PMID: 5009705.

122. Stadnicki A, DeLa Cadena RA, Sartor RB, Bender D, Kettner CA, Rath HC, Adam A, Colman RW. Selective plasma kallikrein inhibitor attenuates acute intestinal inflammation in Lewis rat. Dig Dis Sci. 1996; 41:912–920. PMID: 8625762.

123. McCall RD, Haskill S, Zimmermann EM, Lund PK, Thompson RC, Sartor RB. Tissue interleukin 1 and interleukin-1 receptor antagonist expression in enterocolitis in resistant and susceptible rats. Gastroenterology. 1994; 106:960–972. PMID: 8144001.

124. Yamada T, Sartor RB, Marshall S, Specian RD, Grisham MB. Mucosal injury and inflammation in a model of chronic granulomatous colitis in rats. Gastroenterology. 1993; 104:759–771. PMID: 7680014.

125. Marcus R, Watt J. Colonic ulceration in young rats fed degraded carrageenan. Lancet. 1971; 2:765–766. PMID: 4106253.

126. Watt J, Marcus R. Experimental ulcerative disease of the colon in animals. Gut. 1973; 14:506–510. PMID: 4581171.

127. Moyana T, Lalonde JM. Carrageenan-induced intestinal injury: possible role of oxygen free radicals. Ann Clin Lab Sci. 1991; 21:258–263. PMID: 1859164.

128. Gross V, Arndt H, Andus T, Palitzsch KD, Schölmerich J. Free radicals in inflammatory bowel diseases pathophysiology and therapeutic implications. Hepatogastroenterology. 1994; 41:320–327. PMID: 7959565.

129. Benard C, Cultrone A, Michel C, Rosales C, Segain JP, Lahaye M, Galmiche JP, Cherbut C, Blottière HM. Degraded carrageenan causing colitis in rats induces TNF secretion and ICAM-1 upregulation in monocytes through NF-kappaB activation. PLoS One. 2010; 5:e8666. PMID: 20072622.